Buchumschlag

Featured Cover

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Kai Markus Schneider, Feng Cao, Helen Ye Rim Huang, Lanlan Chen, Yazhou Chen, Rongpeng Gong, Anastasia Raptis, Kate Townsend Creasy, Jan Clusmann, Felix van Haag, Paul‐Henry Koop, Adrien Guillot, Tom Luedde, Rohit Loomba, Sven Francque, Carolin Victoria Schneider
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
von: Maral Amangurbanova, et al.
Veröffentlicht: (2024)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
von: Luis Antonio Díaz, et al.
Veröffentlicht: (2025)

A Message From the Editors
von: Colin W. Howden, et al.
Veröffentlicht: (2024)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
von: Selena Z. Kuo, et al.
Veröffentlicht: (2025)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
von: Samer Gawrieh, et al.
Veröffentlicht: (2024)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
von: Maryam Zafer, et al.
Veröffentlicht: (2025)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
von: Luis Antonio Díaz, et al.
Veröffentlicht: (2025)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
von: Donghee Kim, et al.
Veröffentlicht: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
von: Donghee Kim, et al.
Veröffentlicht: (2025)

Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia—Results of a Post Hoc Analysis of the Phase 3 PALISADE Study
von: Rohit Loomba, et al.
Veröffentlicht: (2026)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
von: Nikita Mittal, et al.
Veröffentlicht: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
von: Matheus Souza, et al.
Veröffentlicht: (2026)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
von: Mazen Noureddin, et al.
Veröffentlicht: (2025)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
von: Takao Miwa, et al.
Veröffentlicht: (2026)

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
von: Lana Bridi, et al.
Veröffentlicht: (2024)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
von: Maral Amangurbanova, et al.
Veröffentlicht: (2024)

Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
von: Harris Siddiqi, et al.
Veröffentlicht: (2024)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance. Authors' Reply
von: Rohit Mehtani, et al.
Veröffentlicht: (2026)

Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
von: Matthew J. Townsend, et al.
Veröffentlicht: (2024)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
von: Amy Sangam, et al.
Veröffentlicht: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
von: Nabil Noureddin, et al.
Veröffentlicht: (2024)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
von: Matthias Kelm, et al.
Veröffentlicht: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
von: Veeral Ajmera, et al.
Veröffentlicht: (2026)

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
von: Daniela S. Allende, et al.
Veröffentlicht: (2024)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
von: Darren Jun Hao Tan, et al.
Veröffentlicht: (2024)

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
von: Shiva Poola, et al.
Veröffentlicht: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
von: Suzanne Sharpton, et al.
Veröffentlicht: (2026)

Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms
von: Olafur S. Palsson, et al.
Veröffentlicht: (2024)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
von: Chun‐Chieh Chen, et al.
Veröffentlicht: (2025)

Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study
von: Clara Yzet, et al.
Veröffentlicht: (2025)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
von: Vincent L. Chen
Veröffentlicht: (2025)

Epidemiology, Predictors of Antimicrobial Resistance and Empiric Treatment Strategies for Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicentre SBP ‐ INDIA Study
von: Nipun Verma, et al.
Veröffentlicht: (2026)